By Elric Langton | 12 May 2022
I have a financial interest Poolbeg Pharma
Poolbeg Pharma Plc (AIM: POLB, OTCQB: POLBF), a clinical-stage infectious disease pharmaceutical company with a unique capital-light clinical model, has announced it has signed a contract for GMP manufacturing of POLB 001 which will ensure it has an ample supply of the severe influenza treatment for use in our upcoming LPS human challenge trial due to commence this coming June 2022. As you know the company plans to monetise this asset via out-licensing or partnership with pharma/biotech companies early next year following receipt of the early human efficacy from our clinical trial later this year. Β